StockNews.com Initiates Coverage on Enzo Biochem (NYSE:ENZ)

StockNews.com began coverage on shares of Enzo Biochem (NYSE:ENZFree Report) in a research note released on Sunday morning. The brokerage issued a hold rating on the medical research company’s stock.

Enzo Biochem Price Performance

Shares of NYSE:ENZ opened at $0.33 on Friday. The business’s 50 day simple moving average is $0.36 and its 200-day simple moving average is $0.63. Enzo Biochem has a 12 month low of $0.25 and a 12 month high of $1.28.

Enzo Biochem (NYSE:ENZGet Free Report) last announced its quarterly earnings results on Monday, March 17th. The medical research company reported ($0.02) EPS for the quarter. The firm had revenue of $7.33 million for the quarter. Enzo Biochem had a negative return on equity of 7.96% and a negative net margin of 75.34%.

Institutional Investors Weigh In On Enzo Biochem

Several institutional investors have recently modified their holdings of ENZ. Virtu Financial LLC purchased a new stake in Enzo Biochem in the 4th quarter valued at approximately $35,000. Lepercq Multi Asset Fund purchased a new stake in Enzo Biochem in the 4th quarter valued at approximately $88,000. Lepercq De Neuflize Asset Management LLC lifted its stake in Enzo Biochem by 27.1% in the 1st quarter. Lepercq De Neuflize Asset Management LLC now owns 156,303 shares of the medical research company’s stock valued at $58,000 after buying an additional 33,303 shares in the last quarter. Wittenberg Investment Management Inc. lifted its stake in Enzo Biochem by 60.1% in the 4th quarter. Wittenberg Investment Management Inc. now owns 187,537 shares of the medical research company’s stock valued at $134,000 after buying an additional 70,400 shares in the last quarter. Finally, Mink Brook Asset Management LLC purchased a new stake in Enzo Biochem in the 4th quarter valued at approximately $577,000. Hedge funds and other institutional investors own 36.90% of the company’s stock.

About Enzo Biochem

(Get Free Report)

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.

Recommended Stories

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.